Truist reiterates Buy on UnitedHealth stock, keeps $500 target
Truist reiterated a Buy rating and $500 price target on UnitedHealth (UNH) after its Q3 results. UNH reported $112.7B revenue, beating estimates, and raised its 2026 EPS guidance to at least $20.50. The company's medical care ratio and operating cost ratio also exceeded expectations.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh, material information for traders.
Market read
UNH's strong earnings and raised outlook are likely to move the stock and impact health‑care sector sentiment.
What to watch
Potential cost pressures from medical care ratio trends could temper long‑term upside.
Background
The article summarizes UnitedHealth's Q3 earnings release and analyst reiteration of a Buy rating with a $500 price target.
Ticker impact
UnitedHealth reported Q3 revenue of $112.7B beating estimates and raised FY2026 adjusted EPS guidance to at least $20.50.
likely upward pressure as investors price in higher earnings outlook
The EPS guidance lift is material for a mega‑cap health insurer and typically triggers buying.
Market effects
Health‑care insurers may see broader valuation lifts on earnings beat.
U.S. market sentiment likely improves in the health‑care sector.
Large‑cap U.S. health insurer results influence global health‑care equity sentiment.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- analystTruist Securities
Reiterated Buy rating and $500 target.
- analystBernstein SocGen Group
Maintained Outperform rating with $512 target.
